JPRN-jRCT1080224100已完成3 期
Multi-center prospective trial of NP028 for patients with peripheral artery disease
IPRO CORPORATIO0 个研究点目标入组 207 人开始时间: 2018年10月18日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 207
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable(—)
- 性别
- All
入选标准
- •Clinical inclusion criteria
- •- Rutherford classification of 2-4 in the target limb
- •- Patient is eligible for percutaneous transluminal angioplasty
- •Angiographic inclusion criteria (by visual estimation)
- •- Target lesion that meets any of the following
- •a. de novo lesion
- •New lesion, or restenosis, reoccluded lesion after 3 months or more has passed after treatment by plain, non-slipping, or cutting balloon catheter (without stent)
- •b. ISR lesion
- •Restenosis, reoccluded lesion which is the after 6 months or more has passed after treatment by bare-metal stent, or the after 12 months or more has passed after treatment by drug eluting stent.
- •- Target lesion that meets any of the following
- •a. Lesion having a stenosis rate of 70% or more and less than 100%, and a lesion length of 5 cm or more and 20 cm or less
- •b. Occluded lesion having a lesion length of 5 cm or more and 10 cm or less
- •c. Tandem lesion having a stenosis rate of 70% or more, and a total combined lesion length of 5 cm or more and 20 cm or less (if there is an occluded part, the length of that lesion should be 10 cm or less)
- •- Target vessel diameter should be 4.0 mm to 8.0 mm
排除标准
- •Clinical exclusion criteria
- •- Not a suitable candidate for DAPT
- •- Known allergy to contrast agent
- •- Dialysis, history or complication of renal dysfunction (Creatinine value exceeds 2.0 mg/dl)
- •- Female of child-bearing potential
- •- Currently participating in an investigational drug or device study, or clinical trial
- •- In cases where the Investigator determines that the patient's participation in the trial is inappropriate
- •Angiographic exclusion criteria
- •- Vessel having an untreated thrombus
- •- Vessel which is necessary to treat by stent, DCB, penetration device, atherectomy, laser catheter, or unapproved device, before using NP028 during procedure
- •- Severe calcified lesion judged to be less than 50 % residual stenosis rate by treatment with PTA balloon catheter
- •- Restenosis or reoccluded lesion which has been performed multiple treatments in the past
- •ISR lesion which is an only second time restenosis or reocclusion that is more than 3 months after treatment with balloon catheter can be included
研究者
相似试验
招募中
4 期
A multicenter controlled trial of NP029 in patients with dialysis shunt insufficiencydialysis shunt failureJPRN-jRCT2032220478shima yasuhiro130
进行中(未招募)
1 期
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer.BRCA1 / BRCA2 associated or unselected Metastatic Breast Cancer.MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-006108-11-ESPharma Mar, S.A.117
已完成
2 期
Multicenter Phase II Clinical Study of the research on optimal assessments and treatment strategy of nilotinib in newly diagnosed chronic myelogenous leukemia patients in the chronic phase (CML-CP) based on early achievement of complete molecular response (CMR); N-roadChronic Myelogenous LeukemiaJPRN-UMIN000008565Cooperative study between Jikei University Kashiwa Hospital and Shimousa Hematology Study Group50
进行中(未招募)
不适用
P01 - A prospective, randomized, multicenter trial of additional radiochemotherapy to neoadjuvant chemotherapy in patients with locally advanced pancreatic adenocarcinomaEUCTR2013-001028-21-ATABCSG (Austrian Breast & Colorectal Cancer Study Group)
进行中(未招募)
不适用
Essai de phase II multicentrique sur le traitement préventif de la folliculite induite par les anti-EGFR chez des patients atteints de cancer colorectal métastatique sous Cetuximab ou atteints de cancer bronchique non à petites cellules sous Erlotinib - DIPROCOCancer colorectal métastatique exprimant l’EGFR et cancer bronchique non à petites cellules localement avancé ou métastatique, exprimant l’EGFRMedDRA version: 9.1Level: LLTClassification code 10025044Term: Lung cancerMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2007-002913-38-FRCentre Oscar Lambret
